HeartSciences Inc. Form 8-K Filing

HeartSciences Inc. (HeartSciences or the Company) issued a press release on September 15, 2026, detailing its financial and operating results for the fiscal first quarter ended July 31, 2026, and providing business updates. The Company is progressing with its proposed merger with Fortitude Mining Holdings, Inc. (Fortitude), a digital asset mining platform, with the transaction expected to close in Q4 2026, subject to shareholder approval. Fortitude has recently executed a purchase agreement for new miners, energized a facility in Nebraska, and acquired another facility in Prosser, Nebraska. In August 2026, Fortitude subscribed for approximately $1.0 million of HeartSciences' common stock. HeartSciences is concentrating its commercial efforts on its MyoVista Insights platform, a device-agnostic ECG management and AI orchestration platform. The company has signed its first US commercial agreements, made the platform available with a third-party AI-ECG algorithm, and was selected as the AI-ECG delivery platform for a major European reference center. The company has also filed for a patent for ECG-based assessment of diastolic function. The FDA 510(k) submission for the MyoVista wavECG device is under review, but the company has recorded a reserve against the related inventory and does not intend to commit significant additional resources to its commercialization due to the emergence of cloud-based AI-ECG algorithms. HeartSciences reported no significant revenue for FQ1 2027, with a loss from operations of $2.9 million. The net loss for FQ1 2027 was $3.2 million. As of July 31, 2026, the Company had a shareholders' deficit of $2.0 million. Subsequent to the period end, the Company raised approximately $1.0 million from Fortitude, $1.2 million from its at-the-market facility, and exchanged $200,000 of principal under a promissory note for shares.